Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01313351 · ClinicalTrials.gov registry record
RPS InflammaDry Detector™ to Determine MMP-9 Levels in Tears
A clinical trial, sponsored by Rapid Pathogen Screening.
- Completed
- Registry status
- 206
- Enrollment target
NCT01313351 is a clinical trial that has completed, run by Rapid Pathogen Screening. The registered enrollment target is 206 participants.
The verdict
NCT01313351 has completed, sponsored by Rapid Pathogen Screening.
- COMPLETED
- Registry status
- 206 participants
- Enrollment target
Study Summary
The RPS InflammaDry Detector™ is intended to detect elevated MMP-9 in human tears to aid in the diagnosis of patients with signs or symptoms of dry eye disease, in conjunction with other methods of clinical evaluation.
Interventions
- DEVICE RPS InflammaDry Detector™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01313351
The ClinicalTrials.gov registry entry for NCT01313351 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rapid Pathogen Screening, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RPS InflammaDry Detector™ is the first listed.
NCT01313351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01313351 about?
NCT01313351 is a clinical study titled "RPS InflammaDry Detector™ to Determine MMP-9 Levels in Tears". The RPS InflammaDry Detector™ is intended to detect elevated MMP-9 in human tears to aid in the diagnosis of patients with signs or symptoms of dry eye disease, in conjunction with other methods of clinical evaluation.
What is the current status of trial NCT01313351?
This trial is currently completed. The enrollment target is 206 participants. The study started on 2010-11. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01313351?
The interventions under investigation include: RPS InflammaDry Detector™ (DEVICE).
Who is sponsoring clinical trial NCT01313351?
This trial is sponsored by Rapid Pathogen Screening, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.